Previous 10 | Next 10 |
2023-11-22 10:00:14 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
2023-11-21 09:59:42 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
2023-11-21 08:16:38 ET Losers: Morphosys AG ( MOR ) -24% . Sibanye Stillwater Limited ( SBSW ) -23% . reAlpha Tech Corp. ( AIRE ) -14% . Alzamend Neuro ( ALZN ) -16% . American Eagle Outfitters AEO -13% after Q3 earning release ....
2023-11-21 04:52:38 ET Related stories Symbotic Inc. (SYM) Q4 2023 Earnings Call Transcript Agilent Technologies, Inc. (A) Q4 2023 Earnings Call Transcript MorphoSys: Buying Constellation Was A Desperate Measure For further details see: Biggest stock move...
2023-11-21 04:52:38 ET Related stories Symbotic Inc. (SYM) Q4 2023 Earnings Call Transcript Agilent Technologies, Inc. (A) Q4 2023 Earnings Call Transcript MorphoSys: Buying Constellation Was A Desperate Measure For further details see: Biggest stock move...
2023-11-20 17:34:17 ET Symbotic ( SYM ) +20% . Veradigm ( MDRX ) +6% . Tactile Systems Technology ( TCMD ) +6% . Farmer Brothers Company ( FARM ) +4% . Outset Medical ( OM ) +4% . MorphoSys ( MOR ) -32% ...
2023-11-20 17:12:31 ET More on MorphoSys MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating) MorphoSys AG 2023 Q3 - Results - Earnings Call Presentation I-Mab gains FDA breakth...
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%) The key secondary endpoints assessing symptom reduction, TSS50 and absolute change in TSS, showe...
MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%) The key secondary endpoints assessing symptom reduction, TSS50 and absolute change in TSS, showed significant improvements for intermediate-risk patients (p<0.05, p<0.02, respectively) and strong n...
2023-11-20 13:26:45 ET Summary MorphoSys AG has faced disappointments with some of its programs not performing well in trials and in the market. The company's recent acquisition of Constellation Pharma is seen as a desperate measure by analysts. The upcoming release of topline...
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...